We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Discovered For Chronic Kidney Disease Prognosis

By LabMedica International staff writers
Posted on 18 Aug 2016
Chronic kidney disease (CKD) is a critical health problem and CKD patients are highly prevalent throughout the world, and the number of end-stage kidney disease (ESKD) patients, who need to receive cost-prohibitive kidney replacement therapy, is increasing year by year.

Currently, there is no effective method to predict the prognosis of chronic kidney disease (CKD) patients, but scientists have now found that measuring D-amino acids, which present only trace in human, provides prognostic information of CKD. D-amino acids, the enantiomers of L-amino acids, are increasingly recognized as potential biomarkers in several diseases.

Nephrologists at the Osaka University Graduate School of Medicine (Osaka, Japan) prospectively enrolled 118 consecutive patients with CKD stages 3, 4 and 5, who were not on dialysis, from a single nephrology department between August 2005 and January 2009. Baseline blood samples from patients after an overnight fast were collected into plastic tubes to prepare plasma.

The enantiomers of amino acids were quantified using the micro two-dimensional high performance liquid chromatography (2D-HPLC) platform. The 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD)-derivatives of the amino acids were separated using a reversed-phase column (Shiseido, Tokyo, Japan). The retention time of NBD-amino acids were determined by authentic amino acid enantiomers, and the amounts were determined by the calibration lines. All the quantitative data were obtained by the fluorescence detection. In the second dimension, HPLC-mass spectrometry (MS/MS) was used to confirm the presence of D-amino acids in the real biological matrices. API-5000 and Triple Quad 5500 (AB Sciex, Framingham, MA, USA) were used as MS/MS instruments.

The scientists found that 16 out of 21 D-amino acids were detected in blood from CKD patients. Further analyses revealed that D-Serine and D-Asparagine were associated with the progression of CKD; the risk of progression to ESKD was elevated from two- to four- fold in those with higher levels of those D-amino acids. The authors concluded that their study will provided the novel method to the clinician which can identify CKD patients at high-risk for progression to ESKD. The information of D-amino acids would enable to select the best treatment for individual person, as well as the discovery of novel therapy.

This method is also applicable to such diseases as life style-associated diseases, such as diabetes mellitus and hypertension and cardiovascular diseases, as the prognoses of these diseases are strongly influenced by CKD progression. The study was published originally published online on May 18, 2016, in the journal Scientific Reports.

Related Links:
Osaka University Graduate School of Medicine
Shiseido
AB Sciex

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test can find tRNA fragments unique to Parkinson’s disease before patients even have symptoms (Photo courtesy of Shutterstock)

Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease

Currently, no reliable blood test exists for diagnosing Parkinson’s disease. Instead, physicians rely on observing a patient's movements, but this qualitative method has an error rate of 20%-25% and can... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.